The obligate intracellular pathogen Chlamydia pneumoniae. Clinical Investigation and Reports
|
|
- Darrell Norman
- 5 years ago
- Views:
Transcription
1 Clinical Investigation and Reports Chlamydia pneumoniae Infection in Circulating Human Monocytes Is Refractory to Antibiotic Treatment Jens Gieffers, MD; Henriette Füllgraf; Jürgen Jahn, MD; Matthias Klinger, MD; Klaus Dalhoff, MD; Hugo A. Katus, MD; Werner Solbach, MD; Matthias Maass, MD Background Recovery of the intracellular bacterium Chlamydia pneumoniae from atherosclerotic plaques has initiated large studies on antimicrobial therapy in coronary artery disease. The basic concept that antibiotic therapy may eliminate and prevent vascular infection was evaluated in vitro and in vivo by examining the antibiotic susceptibility of C pneumoniae in circulating human monocytes, which are thought to transport chlamydiae from the respiratory tract to the vascular wall. Methods and Results Blood monocytes (CD14 ) from 2 healthy volunteers were obtained before and after oral treatment with azithromycin or rifampin and then inoculated with a vascular C pneumoniae strain and continuously cultured in the presence of the respective antibiotic. Progress of infection and chlamydial viability was assessed by immunogoldlabeling and detection of C pneumoniae specific mrna transcripts. Circulating monocytes from patients undergoing treatment with experimental azithromycin for coronary artery disease were examined for C pneumoniae infection by cell culture. Antibiotics did not inhibit chlamydial growth within monocytes. Electron microscopy showed development of chlamydial inclusion bodies. Reverse transcription polymerase chain reaction demonstrated continuous synthesis of chlamydial mrna for 10 days without lysis of the monocytes. The in vivo presence of viable pathogen not eliminated by azithromycin was shown by cultural recovery of C pneumoniae from the circulating monocytes of 2 patients with coronary artery disease. Conclusions C pneumoniae uses monocytes as a transport system for systemic dissemination and enters a persistent state not covered by an otherwise effective antichlamydial treatment. Prevention of vascular infection by antichlamydial treatment may be problematic: circulating monocytes carrying a pathogen with reduced antimicrobial susceptibility might initiate reinfection or promote atherosclerosis by the release of proinflammatory mediators. (Circulation. 2001; 103: ) Key Words: Chlamydia pneumoniae atherosclerosis infection azithromycin rifampin The obligate intracellular pathogen Chlamydia pneumoniae has been related to atherosclerosis by seroepidemiology, detection of chlamydial structures and, most recently, recovery of viable chlamydiae from atherosclerotic plaques. 1,2 Chlamydiae may thus have a role in the multifactorial pathogenesis of atherosclerosis, a chronic inflammatory condition of the vascular wall. 3,4 On the basis of these findings, antimicrobial treatment studies are currently underway, with the intention to improve the clinical condition of patients with coronary artery disease (CAD) by chlamydial eradication from atheromatous plaques. 5 Endothelial and smooth muscle cells can acquire a productive chlamydial infection that can be inhibited in vitro by common antichlamydial antibiotics. 6 However, chlamydiae are notorious for causing chronic infections, 7 and treatment failure is common. These infections and failures may be due to the establishment of a nonreplicating but viable state of chlamydiae in the host cells. 8 Systemic dissemination of C pneumoniae from the respiratory tract to the cells of the vascular wall requires a cellular transport system, because chlamydiae replicate exclusively within their host cells. The elementary body, the metabolically inactive extracellular life stage of chlamydiae, has never been found circulating free within the bloodstream. Circulating monocytes, which are pivotal to the development of atherosclerosis, are known to migrate into the vascular wall. Recent studies have described the in vitro infection of monocyte-derived macrophages with C pneumoniae 9 and the presence of chlamydial DNA within peripheral blood mononuclear cells from patients with CAD. 10,11 Furthermore, C pneumoniae resists digestion in monocytes for 3 days, at least Received October 24, 2000; revision received December 12, 2000; accepted December 14, From the Institute of Medical Microbiology and Hygiene (J.G., H.F., W.S., M.M.), the Department of Internal Medicine II (J.J., K.D., H.A.K.), and the Institute of Anatomy (M.K.), Medical University of Lübeck, Lübeck, Germany. This article originally appeared Online on January 2, 2001 (Circulation. 2001;103:r1 r6). Correspondence to Matthias Maass, MD, Institute of Medical Microbiology and Hygiene, Medical University of Lübeck, Ratzeburger Allee 160, D Lübeck, Germany. maass@hygiene.mu-luebeck.de 2001 American Heart Association, Inc. Circulation is available at 351
2 352 Circulation January under in vitro cell culture conditions. 12 Thus, monocytes are a potential carrier system for C pneumoniae. We were concerned that a persistent chlamydial infection with reduced antibiotic susceptibility might exist in monocytes in vivo and that it might interfere with the basic concept of antimicrobial treatment in coronary heart disease. If monocyte infection is not eliminated by therapeutic intervention, continuous transmission to vascular cells after a decline of the antibiotic tissue levels might affect long-term benefits. Therefore, we studied chlamydial growth and activity within monocytes in the presence of rifampin, the most effective antichlamydial drug in vitro, 13 and azithromycin, a macrolide widely used in current treatment trials. 5 To detect the pathogen, we used immunoelectron microscopy and Chlamydiaspecific mrna transcripts, which are markers of bacterial viability due to their short half-life. In addition, we attempted to culture C pneumoniae from monocytes of patients with unstable angina pectoris who were enrolled in a current trial on the benefit of azithromycin in CAD. Methods In Vitro and Ex Vivo Infection of Human Monocytes in the Presence of Antibiotics To asses the in vitro effect of antibiotics on the development of C pneumoniae in human blood monocytes, CD-14 positive cells were infected with the CV-3 coronary artery isolate of C pneumoniae 1 in the presence of rifampin or azithromycin. Human blood monocytes from 2 healthy male volunteers (28 and 36 years) were separated using a Ficoll-Histopaque density gradient (Sigma) and subsequent positive selection with anti CD-14 microbeads (MACS system, Miltenyi Biotec GmbH). A total of 10 4 CD-14 positive cells per well were inoculated with 10 6 inclusion-forming units of C pneumoniae strain CV-3 and continuously cultivated in 12-well tissue culture plates for up to 10 days in RPMI medium (10% FCS; Gibco/BRL) without antibiotics, with 10 g/ml azithromycin (Pfizer), or with 10 g/ml rifampin (Sigma). Antibiotics were added simultaneously with the chlamydiae. Two hours after inoculation, monocytes were washed once with PBS to remove nonphagocytized elementary bodies, and fresh medium with the respective antibiotic was added. For immunoelectron microscopy, cells were grown on Thermanox coverslips (Nalgene Nunc International) and collected at day 3. For reverse transcription polymerase chain reaction (RT-PCR) detection of chlamydial mrna synthesis, 10 4 cells were collected after 2 hours and 1, 3, and 10 days. Experiments were made in duplicate. The culture assay was repeated after oral treatment of the monocyte donors with azithromycin (Zithromax, Pfizer GmbH; 500 mg/d for 3 days) or rifampin (Rifa, Grünenthal GmbH; 600 mg/d for 6 days). Serum drug concentrations were determined 2 hours after the last application by high-performance liquid chromatography (azithromycin, 0.2 g/ml; rifampin, 18.7 g/ml). Monocytes were collected 2 hours after the last dose, inoculated with CV-3, and cultivated for up to 10 days in the presence of azithromycin (10 g/ml) or rifampin (10 g/ml), as described above. Monocytes collected before the first application of the antibiotic and infected with CV-3 in the absence of any antibiotics served as positive controls; uninfected monocytes served as negative controls. After 2 hours and 1, 3, and 10 days, viability of monocytes in culture was proven by Trypan blue staining. Successful inoculation was controlled by immunofluorescence staining with an anti C pneumoniae antibody (Dako); 10 4 cells were collected for RT-PCR detection of chlamydial mrna synthesis. Experiments were made in duplicate. In a control experiment, immortalized laryngeal epithelial cells (HEp-2, ATCC CLL 23) were infected with C pneumoniae with and without addition of azithromycin (10 g/ml) or rifampin (10 g/ml), as described previously. 13 RT-PCR for chlamydial mrna detection was performed 24 hours and 72 hours after infection. Immunoelectron Microscopy Cells grown on Thermanox slides were fixed with 2% paraformaldehyde and 0.1% glutaraldehyde in PBS (ph 7.4) for 1 hour at 4 C and contrasted with 2% uranyl acetate in cacodylate buffer. After dehydration in a graded acetone series, cells were embedded in LR White (London Resin Co). Ultrathin sections were mounted on 300 mesh nickel grids and were blocked for 30 minutes with 0.5% bovine serum albumin (Sigma) in Tris-buffered saline (TBS). The sections were incubated for 16 hours with chlamydia genus specific mouse anti-hsp60 IgG (Affinity BioReagents) diluted 1:250 with TBS. After rinsing with TBS, sections were incubated for 2 hours with donkey anti-mouse IgG coupled to 12-nm gold particles (Jackson ImmunoResearch) diluted 1:100 with TBS. Sections were contrasted with uranyl acetate and lead citrate and were examined for immunogold-stained chlamydial structures with a Philips EM 400 electron microscope. In control incubations, normal mouse serum was substituted for the primary antibody. Chlamydial mrna Synthesis in the Presence of Antibiotics C pneumoniae specific mrna was extracted by standard methods using TRIZOL Reagent (Gibco/BRL). RT of RNA and cdna amplification was performed using the Access RT-PCR System (Promega) according to the manufacturer s instructions. cdna synthesis was performed at 48 C for 50 minutes. After 2 minutes of initial denaturation at 95 C, the samples were subjected to 40 cycles of denaturation (95 C, 40 s), annealing (55 C, 90 s), and extension (70 C, 120 s), followed by a final extension at 70 C for 10 minutes. Targets were the genes of the major outer membrane protein (MOMP) and the 60-kDa heat shock protein (HSP60). Primers for MOMP mrna were Cpn 201 (5 TGGTCTCGAGCAACTTTT- GATG3 ) and Cpn 202 (5 AGCTCCTACAGTAACTCCACA3 ), as originally described by Gaydos et al. 14 Primers for the HSP60 mrna were GE-1 (5 AGCTCACGTAGTTATAGATAAGAG3 ) and GE-2 (5 AAGTAGCTGGAGAGGTATCCACGG3 ), as described by Airenne et al. 12 As a control for the absence of DNA in the RNA preparation, each sample was additionally amplified without prior RT. PCR products were separated on a 2% agarose gel and transferred on a nitrocellulose membrane by vacuum blotting. For improved sensitivity and specificity, nonradioactive DNA hybridization was performed using probes 3 -tailed with digoxigenin-11 dutp/datp (Roche Diagnostics), according to the manufacturer s instructions. Probes were designed according to the sequence of the amplicons and checked for genus-specificity in a BLAST 2.0 search (5 GCAATCTATAGC- GAAGGTCT3 for HSP60 amplicons; 5 TAACATCCGCATTGCT- CAGC3 for MOMP amplicons). C pneumoniae Culture From Monocytes of CAD Patients Under Azithromycin Treatment Two male patients (68 and 57 years) admitted to our emergency room because of acute chest pain were diagnosed as having unstable angina pectoris on the basis of coronary angiography, electrocardiography, clinical presentation, and laboratory parameters. The first patient was admitted with a myocardial infarction of the inferior wall. Coronary angiography showed 2-vessel disease (right coronary artery and left circumflex artery). The occluded right coronary artery was reopened by PTCA. The patient s risk factors were diabetes mellitus, arterial hypertension, and smoking. The second patient was admitted for a myocardial infarction of the anterior wall. Two-vessel disease (left anterior descending artery and left circumflex artery) was documented by coronary angiography, and the occluded left anterior descending artery was reopened by PTCA. Risk factors in this patient were arterial hypertension and obesity. After informed consent was given, both patients were enrolled in an ongoing clinical trial on the benefit of azithromycin in CAD and received oral courses of 500 mg/d azithromycin on days 1 to 3 and
3 Gieffers et al Refractory C pneumoniae Infection in Monocytes 353 Figure 1. Immunogold-labeling for chlamydia HSP60 in isolated human monocytes (CD14 ) infected in presence of 10 g/ml azithromycin after 3 days (A, B). Infected but untreated epithelial HEp-2 cells served as controls (C). Inoculation of monocytes in presence of azithromycin resulted in development of chlamydial inclusion bodies, as indicated by accumulation of gold particles. These inclusions were frequently of aberrant morphology in comparison with those seen in epithelial cells. They were less dense and contained fewer reticulate and elementary bodies. Identical inclusions were produced in medium without antibiotic supplementation. Bars indicate 0.5 m. on days 14 to 16 after coronary angiography. These patients yielded a positive result for C pneumoniae DNA in their peripheral blood mononuclear cells, which were collected at day 1, as determined in a previously described nested PCR technique. 15 Thus, CD14-positive cells from 8 ml of blood were isolated on day 28, as described above, and subjected to C pneumoniae culture. Separated CD14- positive cells were disrupted with glass beads on a vortex and centrifuged onto HEp-2-cell monolayers in 6-well tissue culture plates and cultured in serial subcultures, as described previously for vascular materials. 1 Productive infection was detected by immunofluorescence using a C pneumoniae monoclonal antibody (Syva, Dako). Results Chlamydial Growth in the Presence of Antibiotics Rifampin and azithromycin had no discernible effect on chlamydial growth and metabolic activity within monocytes in vitro. Inoculation of the freshly isolated human monocytes resulted in the development of inclusion bodies after 3 days whether antibiotics were added or not. These inclusions were proven to be of chlamydial origin by staining with the anti-chlamydial HSP60 antibody using immunoelectron microscopy. However, the inclusions were frequently of aberrant morphology in comparison with those seen in epithelial cells. They contained fewer and less dense reticulate and elementary bodies (Figure 1). mrna Synthesis in the Presence of Antibiotics and After Prior Systemic Antibiotic Treatment Chlamydiae within monocytes were metabolically active and did not cause host cell lysis; thus, they were proven to persist. Infected CD14-positive cells were viable until the end of the experiment (10 days), as shown by Trypan blue and immunofluorescence staining. RT-PCR demonstrated chlamydial HSP60 and MOMP mrna synthesis, which indicated the viability of the pathogen in the presence of azithromycin or rifampin at 2 hours and 1, 3, and 10 days after infection. Similarly, mrna transcripts of HSP60 and MOMP were continuously expressed from 2 hours to 10 days, despite of prior systemic treatment of the monocyte donors with conventional courses of the respective antibiotics and their permanent presence in the culture medium (Figure 2). In a control experiment, synthesis of HSP60 and MOMP mrna ceased completely in infected HEp-2 cells treated with azithromycin or rifampin within 72 hours, thus demonstrating the in vitro efficiency of the antibiotics in epithelial cells in the same setting (Figure 3). Cultural Recovery of C pneumoniae Under Azithromycin Treatment Viable C pneumoniae was isolated and continuously cultured from CD14-positive cells of both CAD patients who had undergone azithromycin treatment. Prior treatment with azithromycin did not eradicate C pneumoniae from circulating monocytes. The minimal inhibitory concentration of azithromycin, as determined in a standard system in laryngeal HEp-2 cells, 13 was 0.08 g/ml for both strains. There was no evidence that the patients suffered from a systemic inflammatory response syndrome, according to current consensus criteria. 16 Discussion There are 2 main findings in this study: (1) monocytes can disseminate the viable respiratory pathogen C pneumoniae within the systemic circulation, and (2) the pathogen cannot be eliminated from its monocyte host by standard antichlamy-
4 354 Circulation January Figure 2. Detection of C pneumoniae specific HSP60 mrna and MOMP mrna transcripts as markers of viability in infected human monocytes. Chlamydial metabolic activity persists under in vitro application of 10 g/ml azithromycin or rifampin, as well as after oral in vivo pretreatment with azithromycin (3 days, 500 mg/d) or rifampin (5 days, 600 mg/d). Chlamydial mrna transcripts are detectable for at least 10 days, indicating an intracellular infection that is refractory to antibiotic treatment. M indicates DNA marker VIII, digoxigenin-labeled (Boehringer); A, uninfected monocytes; and, C pneumoniae infected monocytes in absence of antibiotics (3 days after infection). dial treatment. The continuous presence of azithromycin or rifampin does not protect cultured human monocytes from C pneumoniae infection in vitro. In addition, monocytes isolated after a standard course of azithromycin or rifampin treatment, and thus already replenished with antibiotics, still acquire C pneumoniae infection when subsequently cultured in the presence of antibiotics. Intracellular development beyond mere phagocytic ingestion was shown electronmicroscopically by immunogold-labeling of reticulate and elementary bodies within inclusions. These inclusions and their content were morphologically different from what is found in the acute infection of epithelial cells, but their viability and metabolic activity was proven by continuous detection of chlamydial mrna transcripts. The pathogen remained viable without initiating the host cell lysis that otherwise marks the end of the regular chlamydial replication cycle. Thus, the monocytes acquire a persistent infection. Finally, the cultural retrieval of C pneumoniae from circulating CD14-positive cells of CAD patients undergoing experimental azithromycin treatment for coronary sclerosis proved the presence of viable chlamydiae in the bloodstream, despite antichlamydial therapy. In this study, we defined systemically circulating CD14- positive cells as hosts for C pneumoniae. This fills the current gap between the respiratory epithelium, the primary target of Figure 3. Eradication of C pneumoniae from epithelial HEp-2 cells by antibiotics (AB). C pneumoniae HSP60 mrna transcripts are detectable in untreated HEp-2 cells 1 and 3 days after infection (inf) but not in cells treated with 10 g/ml azithromycin (Azithro) or rifampin (Rifa). Acute infection can be eliminated in this in vitro setting. M indicates DNA marker VIII, digoxigenin-labeled (Boehringer); A, uninfected HEp-2 cells. this pathogen, and the vascular wall, where the chlamydiae were detected by various techniques, 1,17 19 although their origin remained unexplained. The recovery of C pneumoniae from monocytes now illustrates one method whereby the obligate intracellular organism may gain access to the vascular system. Other studies suggested that monocytes could be a potential vector system for chlamydial distribution on basis of DNA detection within peripheral blood mononuclear cells 10,11 or CD14-positive cells, 15 but these studies lacked evidence of viability. In the lung, C pneumoniae enters epithelial cells and alveolar macrophages, 20 but the exact site of transmission of chlamydiae to blood monocytes remains to be defined. In vitro data indicate that monocytes may transmit C pneumoniae to vascular endothelial cells, 21 but in vivo data are lacking. For initiation or promotion of atherogenesis, however, infection of the vascular wall does not seem mandatory because a release of proinflammatory mediators by circulating or transendothelially migrating infected monocytes might be sufficient. 22 In acute infection, host cells disintegrate and release newly produced elementary bodies within 3 days. In monocytes, however, a persistent infection was established for the observation period of 10 days. This persistent state seems to be typical of chlamydiae ingested by human monocytes under in vitro culture conditions and is not induced by antibiotics, because it occurs without any antibiotic supplementation. In a previous study, C trachomatis serovar K specific mrna was detected in monocytes for 10 days. 23 Airenne et al 12 showed that C pneumoniae was transcriptionally active for 3 days in vitro and did not develop infectious progeny in human monocytes. However, because we were able to culture the organism from monocytes from CAD patients, the data suggest that the ability to replicate is not lost within the monocytes. Interestingly, an establishment of the persistent infection could not be prevented by antichlamydial treatment. Although monocytes were subjected in vitro and in vivo to adequate amounts of antibiotic substance, they still promoted persistent infection with a vascular C pneumoniae strain. When tested under standard susceptibility testing conditions,
5 Gieffers et al Refractory C pneumoniae Infection in Monocytes 355 the very same strain was highly sensitive to rifampin and azithromycin. This may explain the treatment failures seen in respiratory infections with strains that seemed susceptible in vitro. 24 Current chlamydial susceptibility testing is focused on acute infection in epithelial cells and apparently does not apply to persistent infection. The present study suggests that chlamydiae can survive an antichlamydial therapy within monocytes in vitro and in vivo. Optimal regimens for chlamydial eradication from monocytes are not known, but cultural recovery of the pathogen from circulating monocytes after 2 conventional courses of azithromycin treatment clearly indicates that a standard approach, as used in acute lung infection, may not be successful. Thus, endogenous reinfection of vascular cells after a decline of the antibiotic tissue levels cannot be excluded. In fact, this may seriously affect the current efforts made in large prospective trials to alleviate clinical CAD symptoms by antichlamydial treatment. This notion is supported by recent data from ongoing treatment trials. In the largest study on antimicrobial treatment in CAD patients published to date, azithromycin treatment had no significant effects on clinical events after 6 months and 2 years. 25 A statistically significant benefit among roxithromycin-treated CAD patients seen after 30 days in the Roxithromycin Ischemic Syndromes (ROXIS) study was not reproduced after 6 months. 26 Erythromycin or tetracycline treatment within the last 5 years had no effect on the risk of having a first myocardial infarction in a retrospective study. 27 In contrast, another retrospective analysis of first-time myocardial infarction cases and controls reported a favorable effect of tetracycline and quinolone antibiotics but not macrolides. 28 In a rabbit model on the acceleration of atherogenesis by chlamydial infection, azithromycin treatment had a documented protective effect. However, C pneumoniae antigen was still detected in the vessel walls after a 7-week azithromycin course, indicating persistence. 29 It is important to note that antibiotics can inhibit chlamydial growth in the atherogenetically relevant endothelial and smooth muscle cells. 6 Thus, chlamydial eradication from cells other than monocytes/macrophages is potentially feasible. However, there is evidence suggesting that persistence may be established in those cells, too. In a recently described in vitro model of continuous C pneumoniae infection, epithelial cells sustained infection for 2 years without an addition of fresh host cells or chlamydiae. Six-day courses of azithromycin or ofloxacin did not eliminate the infection. 30 It is unknown if this corresponds to the in vivo situation in pulmonary or vascular tissue. In vivo, chlamydial persistence has been observed in only monocytes thus far, but it can be induced in endothelial and epithelial cells in vitro by tryptophan depletion, interferon-, or tumor necrosis factor-. 8,31 When a corresponding mechanism was studied for monocytes, growth inhibition could not be neutralized by tryptophan or interferon- antibodies. 12,23 Apparently, the persistent state can be entered spontaneously in monocytes/macrophages but is dependent on the cytokine network in other cell populations. Nevertheless, the absence of essential nutrients in the vacuole of the intracellular parasite may be the cause of growth arrest. Persistence seems to be the result of a stress response, as indicated by the prominent production of HSP60. We speculate that the altered metabolic condition in this state is also the cause of the ineffectiveness of the antimicrobial agents described in this study and that this state is based on differentially displayed chlamydial genes for cell differentiation, cytokinesis, and stress response. Therefore, we suggest the use of infected monocytes as a model system for further examination of the genetic background of chlamydial persistence and for the definition of targets for the eradication of persisting chlamydiae. An infectious component in the chronic inflammatory condition of atherosclerosis may provide additional explanations for unclear phenomena of atherogenesis, such as mesenchymal cell proliferation and its distinct inflammatory component. The obvious appeal of treating a bacterial pathogen in this setting, the leading cause of death in the industrialized nations, has initiated a variety of prospective antimicrobial intervention studies with patients enrolled. 5 However, evidence is increasing that eradication may face enormous problems due to the chlamydial ability to enter a refractory state of persistent infection that seems unique to chlamydiae. Acknowledgments This study was supported by grants from the Deutsche Forschungsgemeinschaft, Bonn, Germany, to Dr Maass (Ma 2070/2 1 and SFB 367, B11). References 1. Maass M, Bartels C, Engel PM, et al. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol. 1998;31: Ramirez JA, Chlamydia pneumoniae/atherosclerosis Study Group. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary arteriosclerosis. Ann Intern Med. 1996;125: Libby P. Atheroma: more than mush. Lancet. 1996;348(suppl 1): Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340: Grayston JT. Antibiotic treatment trials for secondary prevention of coronary artery disease events. Circulation. 1999;99: Gieffers J, Solbach W, Maass M. Activity of antibiotics in eliminating Chlamydia pneumoniae cardiovascular strains from cell types involved in the pathogenesis of arteriosclerosis. Clin Microbiol Infect. 1999;5(suppl 3):381. Abstract. 7. Ward ME. The immunobiology and immunopathology of chlamydial infections. APMIS. 1995;103: Beatty WL, Byrne GI, Morrison RP. Morphologic and antigenetic characterization of interferon gamma-mediated persistent Chlamydia trachomatis infection in vitro. Proc Nat Acad Sci U S A. 1993;90: Gaydos CA, Summersgill JT, Sahney NN, et al. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun. 1996;64: Boman J, Sonderberg S, Forsberg J, et al. High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors. J Infect Dis. 1998;178: Wong YK, Dawkins KD, Ward ME. Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease. J Am Coll Cardiol. 1999;34: Airenne S, Surcel HM, Alakärppä H, et al. Chlamydia pneumoniae infection in human monocytes. Infect Immun. 1999;67: Gieffers J, Solbach W, Maass M. In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries. Antimicrob Agents Chemother. 1998;42: Gaydos CA, Quinn CT, Bobo LD, et al. Similarity of Chlamydia pneumoniae strains in the variable domain IV region of the major outer membrane protein gene. Infect Immun. 1992;60:
6 356 Circulation January Maass M, Jahn J, Gieffers J, et al. Detection of Chlamydia pneumoniae within peripheral blood monocytes of patients with unstable angina or myocardial infarction. J Infect Dis. 2000;181(suppl 3): The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Crit Care Med: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101: Muhlestein JB, Hammond EH, Carlquist JF, et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular diseases. J Am Coll Cardiol. 1996;27: Kuo CC, Shor A, Campbell LA, et al. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis. 1993;167: Shor A, Phillips JI, Ong G, et al. Chlamydia pneumoniae in atheroma: consideration of criteria for causality. J Clin Pathol. 1998;51: Redecke V, Dalhoff K, Bohnet S, et al. Interaction of Chlamydia pneumoniae and human alveolar macrophages: infection and inflammatory response. Am J Respir Cell Mol Biol. 1998;19: Quinn TC, Gaydos CA. In vitro infection and pathogenesis of Chlamydia pneumoniae in endovascular cells. Am Heart J. 1999;138(suppl): Kol A, Libby P. Molecular mediators of arterial inflammation: a role for microbial products? Am Heart J. 1999;138(suppl): Koehler L, Nettelnbreker E, Hudson AP, et al. Ultrastructural and molecular analysis of the persistence of Chlamydia trachomatis (serovar K) in human monocytes. Microb Pathog. 1997;22: Hammerschlag MR, Chirgwin K, Roblin PM, et al. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis. 1992;14: Muhlestein JB, Anderson JL, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation. 2000;102: Gurfinkel E, Bozovich G, Beck E, et al. Treatment with the antibiotic roxithromycin in patients with acute non-q-wave coronary syndromes. Eur Heart J. 1999;20: Jackson LA, Smith NL, Heckbert SR, et al. Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline. Emerg Infect Dis. 1999;5: Meier CR, Derby LE, Jick SS, et al. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA. 1999;281: Muhlestein J, Jeffrey LA, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 1998;97: Kutlin A, Roblin PM, Hammerschlag MR. In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model. Antimicrob Agents Chemother. 1999;43: Beatty WL, Belanger TA, Desal AA, et al. Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence. Infect Immun. 1994;62:
Growth Cycle-Dependent Pharmacodynamics of Antichlamydial Drugs
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2005, p. 1852 1856 Vol. 49, No. 5 0066-4804/05/$08.00 0 doi:10.1128/aac.49.5.1852 1856.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationEndovascular Presence of Viable Chlamydia pneumoniae Is a Common Phenomenon in Coronary Artery Disease
JACC Vol. 31, No. 4 March 15, 1998:827 32 827 CORONARY ARTERY DISEASE Endovascular Presence of Viable Chlamydia pneumoniae Is a Common Phenomenon in Coronary Artery Disease MATTHIAS MAASS, MD, CLAUS BARTELS,
More informationEffect of Azithromycin plus Rifampin versus That of Azithromycin Alone on the Eradication of Chlamydia pneumoniae
Antimicrobial Agents and Chemotherapy, June 1999, p. 1491-1493, Vol. 43, No. 6 0066-4804/99/$04.00+0 Copyright 1999, American Society for Microbiology. All rights reserved. Effect of Azithromycin plus
More informationCirculating Chlamydia pneumoniae DNA as a Predictor of Coronary Artery Disease
Journal of the American College of Cardiology Vol. 34, No. 5, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00391-5 Circulating
More informationPhagocytes transmit Chlamydia pneumoniae from the lungs to the vasculature.
Eur Respir J 2004; 23: 506 510 DOI: 10.1183/09031936.04.00093304 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2004 European Respiratory Journal ISSN 0903-1936 FRONT ROWS OF SCIENCE Phagocytes
More informationCharacterization of Chlamydia pneumoniae Persistence in HEp-2 Cells Treated with Gamma Interferon
INFECTION AND IMMUNITY, Dec. 2001, p. 7927 7932 Vol. 69, No. 12 0019-9567/01/$04.00 0 DOI: 10.1128/IAI.69.12.7927 7932.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Characterization
More informationEffect of Azithromycin Treatment on Endothelial Function in Patients With Coronary Artery Disease and Evidence of Chlamydia pneumoniae Infection
Effect of Azithromycin Treatment on Endothelial Function in Patients With Coronary Artery Disease and Evidence of Chlamydia pneumoniae Infection Nikhil Parchure, MRCP; Emmanouil G. Zouridakis, MD; Juan
More informationChlamydia pneumoniae in atheroma: consideration of criteria for causality
812 School of Pathology, University of the Witwatersrand, South Africa A Shor National Centre for Occupational Health, Johannesburg, South Africa J I Phillips MRC Sexually Transmitted Diseases Research
More informationProgression of Early Carotid Atherosclerosis Is Only Temporarily Reduced After Antibiotic Treatment of Chlamydia pneumoniae Seropositivity
Progression of Early Carotid Atherosclerosis Is Only Temporarily Reduced After Antibiotic Treatment of Chlamydia pneumoniae Seropositivity Dirk Sander, MD; Kerstin Winbeck, MD; Jürgen Klingelhöfer, MD;
More informationChlamydia pneumoniae Eradication from Carotid Plaques. Results of an Open, Randomised Treatment Study
Eur J Vasc Endovasc Surg 18, 355 359 (1999) Article No. ejvs.1999.0915 Chlamydia pneumoniae Eradication from Carotid Plaques. Results of an Open, Randomised Treatment Study G. Melissano 1, F. Blasi 2,
More informationThe Pathogenesis of Chlamydia pneumoniae in Multiple Sclerosis: Current Thoughts and Future Directions
The Pathogenesis of Chlamydia pneumoniae in Multiple Sclerosis: Current Thoughts and Future Directions Seminars in Pathology March 9, 2010 Charles W. Stratton, M.D. Features of C. pneumoniae Infection
More informationMicrobiology of Atypical Pneumonia. Dr. Mohamed Medhat Ali
Microbiology of Atypical Pneumonia Dr. Mohamed Medhat Ali Pneumonia P n e u m o n i a i s a n infection of the lungs that can be caused by viruses, bacteria, and fungi. Atypical! Pneumonia Symptoms. X-ray
More informationIs atherosclerosis an infectious disease?
REVIEW STEVEN D. MAWHORTER, MD Department of Infectious Disease, Cleveland Clinic MICHAEL A. LAUER, MD Department of Cardiology, Borgess Medical Center Research Institute, Kalamazoo, Michigan Is atherosclerosis
More information322 Chlamydia pneumoniae and Coronary Artery Disease Mayo Clin Proc, March 2003, Vol 78 plaque. 8,9 One theory is that, in certain genetically suscept
Mayo Clin Proc, March 2003, Vol 78 Chlamydia pneumoniae and Coronary Artery Disease 321 Review Chlamydia pneumoniae and Coronary Artery Disease: The Antibiotic Trials JOHN P. HIGGINS, MD, MPHIL Parallel
More informationCHAPTER 4 RESULTS. showed that all three replicates had similar growth trends (Figure 4.1) (p<0.05; p=0.0000)
CHAPTER 4 RESULTS 4.1 Growth Characterization of C. vulgaris 4.1.1 Optical Density Growth study of Chlorella vulgaris based on optical density at 620 nm (OD 620 ) showed that all three replicates had similar
More informationInfection and Atherosclerosis: Evidence for Possible Associations
Cardiovascular Disease Infection and Atherosclerosis: Evidence for Possible Associations I.W. Fong, MB, BS, FRCPC, Department of Medicine, Division of Infectious Diseases, University of Toronto, St. Michael
More informationEpidemiological studies demonstrated an association between
Reduced Progression of Early Carotid Atherosclerosis After Antibiotic Treatment and Chlamydia pneumoniae Seropositivity Dirk Sander, MD; Kerstin Winbeck, MD; Jürgen Klingelhöfer, MD; Thorleif Etgen, MD;
More informationJyotika Sharma, Feng Dong, Mustak Pirbhai, and Guangming Zhong*
INFECTION AND IMMUNITY, July 2005, p. 4414 4419 Vol. 73, No. 7 0019-9567/05/$08.00 0 doi:10.1128/iai.73.7.4414 4419.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. Inhibition
More informationChlamydia pneumoniae Growth Inhibition in Cells by the Steroid Receptor Antagonist RU486 (Mifepristone)
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2008, p. 1991 1998 Vol. 52, No. 6 0066-4804/08/$08.00 0 doi:10.1128/aac.01416-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Chlamydia
More informationChlamydia pneumoniae in arteries: the facts, their interpretation, and future studies
J Clin Pathol 1998;51:793 797 793 Leader Imperial College School of Medicine at St Mary s, London W2, UK D Taylor-Robinson B J Thomas Correspondence to: Professor D Taylor-Robinson, Department of Genitourinary
More informationAntibiotic Treatment of Chlamydia pneumoniae after Acute Coronary Syndrome
The new england journal of medicine original article Antibiotic Treatment of Chlamydia pneumoniae after Acute Coronary Syndrome Christopher P. Cannon, M.D., Eugene Braunwald, M.D., Carolyn H. McCabe, B.S.,
More informationChlamydia pneumoniae Expresses Genes Required for DNA Replication but Not Cytokinesis during Persistent Infection of HEp-2 Cells
INFECTION AND IMMUNITY, Sept. 2001, p. 5423 5429 Vol. 69, No. 9 0019-9567/01/$04.00 0 DOI: 10.1128/IAI.69.9.5423 5429.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Chlamydia
More informationCoronaviruses cause acute, mild upper respiratory infection (common cold).
Coronaviruses David A. J. Tyrrell Steven H. Myint GENERAL CONCEPTS Clinical Presentation Coronaviruses cause acute, mild upper respiratory infection (common cold). Structure Spherical or pleomorphic enveloped
More informationChlamydia. By Madhuri Reddy
Chlamydia By Madhuri Reddy Disease- Chlamydia Etiologic agent Chlamydial infection is caused by the genera Chlamydia, of which the type of species is Chlamydia trachomatis. This infection can causes diseases
More information6/11/15. BACTERIAL STDs IN A POST- HIV WORLD. Learning Objectives. How big a problem are STIs in the U.S.?
BACTERIAL STDs IN A POST- HIV WORLD Tracey Graney, PhD, MT(ASCP) Monroe Community College Learning Objectives Describe the epidemiology and incidence of bacterial STDs in the U.S. Describe current detection
More informationChapter 13 Viruses, Viroids, and Prions. Biology 1009 Microbiology Johnson-Summer 2003
Chapter 13 Viruses, Viroids, and Prions Biology 1009 Microbiology Johnson-Summer 2003 Viruses Virology-study of viruses Characteristics: acellular obligate intracellular parasites no ribosomes or means
More information(A) PCR primers (arrows) designed to distinguish wild type (P1+P2), targeted (P1+P2) and excised (P1+P3)14-
1 Supplemental Figure Legends Figure S1. Mammary tumors of ErbB2 KI mice with 14-3-3σ ablation have elevated ErbB2 transcript levels and cell proliferation (A) PCR primers (arrows) designed to distinguish
More informationIdentification of Microbes Lecture: 12
Diagnostic Microbiology Identification of Microbes Lecture: 12 Electron Microscopy 106 virus particles per ml required for visualization, 50,000-60,000 magnification normally used. Viruses may be detected
More informationMedical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
More informationMyocardial infarction and unstable angina derive from
Clinical Investigation and Reports Effect of 3 Months of Antimicrobial Treatment With Clarithromycin in Acute Non Q-Wave Coronary Syndrome Juha Sinisalo, MD; Kimmo Mattila, MD; Ville Valtonen, MD; Olli
More informationPart II Serology Caroline Bax BW.indd 55 Caroline Bax BW.indd : :17
Part II Serology part II Chapter 4 Comparison of serological assays for detection of Chlamydia trachomatis antibodies in different groups of obstetrical and gynaecological patients C.J. Bax J.A.E.M. Mutsaers
More informationInflammation plays a major role in atherogenesis and rapid
Effect of Treatment for Chlamydia pneumoniae and Helicobacter pylori on Markers of Inflammation and Cardiac Events in Patients With Acute Coronary Syndromes South Thames Trial of Antibiotics in Myocardial
More informationChlamydia pneumoniae and Cardiovascular Disease
Chlamydia pneumoniae and Cardiovascular Disease Lee Ann Campbell, Cho-Chou Kuo, and J. Thomas Grayston University of Washington, Seattle, Washington, USA Chlamydia pneumoniae is a ubiquitous pathogen that
More informationProduction of Interferon Alpha by Dengue Virus-infected Human Monocytes
J. gen. Virol. (1988), 69, 445-449. Printed in Great Britain 445 Key words: IFN-ct/dengue virus/monocytes Production of Interferon Alpha by Dengue Virus-infected Human Monocytes By ICHIRO KURANE AND FRANCIS
More informationMINIREVIEW Antimicrobial Susceptibility and Therapy of Infections Caused by Chlamydia pneumoniae
ANTIMICROBiAL AGENTS AND CHEMOTHERAPY, Sept. 1994, p. 1873-1878 0066-4804/94/$04.00+0 Copyright X 1994, American Society for Microbiology Vol. 38, No. 9 MINIREVIEW Antimicrobial Susceptibility and Therapy
More informationSession 2. TiLV isolation and Koch s Postulates
Session 2 Win Surachetpong DVM, PhD, CertAqV, DTBVP Kathy Tang-Nelson PhD TiLV isolation and Koch s Postulates Learning objectives Describe how viruses are isolated Apply the appropriate method to the
More informationChronic Chlamydophila pneumoniae infection in lung cancer, a risk factor: a case control study
Journal of Medical Microbiology (2003), 52, 721 726 DOI 10.1099/jmm.0.04845-0 Chronic Chlamydophila pneumoniae infection in lung cancer, a risk factor: a case control study Bekir Kocazeybek Correspondence
More informationPresence of Chlamydia pneumoniae in Human Symptomatic and Asymptomatic Carotid Atherosclerotic Plaque
Presence of Chlamydia pneumoniae in Human Symptomatic and Asymptomatic Carotid Atherosclerotic Plaque Ronald LaBiche, PhD; Deloris Koziol, PhD; Thomas C. Quinn, MD; Charlotte Gaydos, DrPH; Salman Azhar,
More informationPersistent Infection of MDCK Cells by Influenza C Virus: Initiation and Characterization
J. gen. Virol. (199), 70, 341-345. Printed in Great Britain 341 Key words: influenza C virus/interferon/persistent infection Persistent Infection of MDCK Cells by Influenza C Virus: Initiation and Characterization
More informationReceived 19 November 1997/Returned for modification 5 January 1998/Accepted 15 January 1998
INFECTION AND IMMUNITY, Apr. 1998, p. 1370 1376 Vol. 66, No. 4 0019-9567/98/$04.00 0 Copyright 1998, American Society for Microbiology Characterization of a Strain of Chlamydia pneumoniae Isolated from
More informationGamma Interferon Production by Cytotoxic T Lymphocytes Is Required for Resolution of Chlamydia trachomatis Infection
INFECTION AND IMMUNITY, Nov. 1998, p. 5457 5461 Vol. 66, No. 11 0019-9567/98/$04.00 0 Copyright 1998, American Society for Microbiology. All Rights Reserved. Gamma Interferon Production by Cytotoxic T
More informationDirect ex vivo characterization of human antigen-specific CD154 + CD4 + T cells Rapid antigen-reactive T cell enrichment (Rapid ARTE)
Direct ex vivo characterization of human antigen-specific CD154 + CD4 + T cells Rapid antigen-reactive T cell enrichment (Rapid ARTE) Introduction Workflow Antigen (ag)-specific T cells play a central
More informationhas been questioned [2] and the situation in the brain may be even more problematic because of the presence of the
Infection 35 2007 No 5 Pp 383-5 Correspondence Antimicrobial Treatment of Multiple Sclerosis Woessner and colleagues [1], in their article Long-term Antibiotic Treatment with Roxithromycin in Patients
More informationBy: Dr Mehrnoosh Shanaki
Resveratrol could partly improve the crosstalk between canonical β-catenin/wnt and FOXO pathways in coronary artery disease patients with metabolic syndrome: A case control study By: Dr Mehrnoosh Shanaki
More informationMulticenter Comparison Trial of DNA Extraction Methods and PCR Assays for Detection of Chlamydia pneumoniae in Endarterectomy Specimens
JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 2001, p. 519 524 Vol. 39, No. 2 0095-1137/01/$04.00 0 DOI: 10.1128/JCM.39.2.519 524.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Multicenter
More informationISOLATION OF A SARCOMA VIRUS FROM A SPONTANEOUS CHICKEN TUMOR
ISOLATION OF A SARCOMA VIRUS FROM A SPONTANEOUS CHICKEN TUMOR Shigeyoshi ITOHARA, Kouichi HIRATA, Makoto INOUE, Masanori Veterinary Pathology, Faculty of Agriculture, Yamaguchi University* HATSUOKA, and
More informationWhere are we heading?
Unit 4: Where are we heading? Unit 4: Introduction Unit 1: Why should we care about infectious diseases? Unit 2: What does it mean to have an infectious disease? Unit 3: When does a microbe become a pathogen?
More informationCell Culture. The human thyroid follicular carcinoma cell lines FTC-238, FTC-236 and FTC-
Supplemental material and methods Reagents. Hydralazine was purchased from Sigma-Aldrich. Cell Culture. The human thyroid follicular carcinoma cell lines FTC-238, FTC-236 and FTC- 133, human thyroid medullary
More informationDespite accumulating evidence that infection predisposes
Prospective Study of Pathogen Burden and Risk of Myocardial Infarction or Death Jianhui Zhu, MD, PhD; F. Javier Nieto, MD, PhD; Benjamin D. Horne, MPH; Jeffrey L. Anderson, MD; Joseph B. Muhlestein, MD;
More informationIn vitro human regulatory T cell suppression assay
Human CD4 + CD25 + regulatory T cell isolation, in vitro suppression assay and analysis In vitro human regulatory T cell suppression assay Introduction Regulatory T (Treg) cells are a subpopulation of
More informationApplication of μmacs Streptavidin MicroBeads for the analysis of HIV-1 directly from patient plasma
Excerpt from MACS&more Vol 8 1/2004 Application of μmacs Streptavidin MicroBeads for the analysis of HIV-1 directly from patient plasma L. Davis Lupo and Salvatore T. Butera HIV and Retrovirology Branch,
More informationRecommended laboratory tests to identify influenza A/H5 virus in specimens from patients with an influenza-like illness
World Health Organization Recommended laboratory tests to identify influenza A/H5 virus in specimens from patients with an influenza-like illness General information Highly pathogenic avian influenza (HPAI)
More informationThe value of urine samples from men with nongonococcal
124 Genitourin Med 1991;67:124-128 The value of urine samples from men with nongonococcal urethritis for the detection of Chlamydia trachomatis P E Hay, B J Thomas, C Gilchrist, H M Palmer, C B Gilroy,
More informationChlamydia pneumoniae Infects and Multiplies in Lymphocytes In Vitro
INFECTION AND IMMUNITY, Dec. 2001, p. 7753 7759 Vol. 69, No. 12 0019-9567/01/$04.00 0 DOI: 10.1128/IAI.69.12.7753 7759.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Chlamydia
More informationRNA/DNA Stabilization Reagent for Blood/Bone Marrow
For general laboratory use. Not for use in diagnostic procedures. FOR IN VITRO USE ONLY. RNA/DNA Stabilization Reagent for Blood/Bone Marrow For simultaneous cell lysis and stabilization of nucleic acids
More informationIn vitro and Intracellular Activities of Peptide Deformylase. Inhibitor GSK against Legionella pneumophila Isolates
AAC Accepts, published online ahead of print on 27 October 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.04006-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 In vitro
More informationNormal blood vessels A= artery V= vein
Normal blood vessels A= artery V= vein Artery (A) versus vein (V) ARTERIOSCLEROSIS Arteriosclerosis ="hardening of the arteries" arterial wall thickening and loss of elasticity. Three patterns are recognized,
More informationHost immune response to Chlamydia pneumoniae heat shock protein 60 is associated with asthma
Eur Respir J 21; 17: 178 182 Printed in UK all rights reserved Copyright #ERS Journals Ltd 21 European Respiratory Journal ISSN 93-1936 Host immune response to Chlamydia pneumoniae heat shock protein 6
More informationLDL Uptake Cell-Based Assay Kit
LDL Uptake Cell-Based Assay Kit Catalog Number KA1327 100 assays Version: 07 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 Principle of the Assay...
More informationBackground and Current Knowledge of Chlamydia pneumoniae and Atherosclerosis
S402 Background and Current Knowledge of Chlamydia pneumoniae and Atherosclerosis J. Thomas Grayston Department of Epidemiology, University of Washington, Seattle Attributes of Chlamydia pneumoniae of
More informationDegradation of Chlamydia pneumoniae by Peripheral Blood Monocytic Cells
INFECTION AND IMMUNITY, Aug. 2005, p. 4560 4570 Vol. 73, No. 8 0019-9567/05/$08.00 0 doi:10.1128/iai.73.8.4560 4570.2005 Degradation of Chlamydia pneumoniae by Peripheral Blood Monocytic Cells Katerina
More informationImaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD
Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD Hein J. Verberne Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands International Conference
More informationUnit II Problem 2 Microbiology Lab: Pneumonia
Unit II Problem 2 Microbiology Lab: Pneumonia - What are the steps needed to obtain a proper sputum specimen? You need the following: A wide-mouth labeled container. Gloves. Water. Mouth wash + tissues.
More informationHepatitis B Antiviral Drug Development Multi-Marker Screening Assay
Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay Background ImQuest BioSciences has developed and qualified a single-plate method to expedite the screening of antiviral agents against
More informationAcute myocardial infarction (MI) on initial presentation was diagnosed if there was 20 minutes
SUPPLEMENTAL MATERIAL Supplemental Methods Diagnosis for acute myocardial infarction Acute myocardial infarction (MI) on initial presentation was diagnosed if there was 20 minutes or more of chest pain
More informationIn vitro human regulatory T cell expansion
- 1 - Human CD4 + CD25 + regulatory T cell isolation, Workflow in vitro expansion and analysis In vitro human regulatory T cell expansion Introduction Regulatory T (Treg) cells are a subpopulation of T
More informationVALVULO-METABOLIC RISK IN AORTIC STENOSIS
January 2008 (Vol. 1, Issue 1, pages 21-25) VALVULO-METABOLIC RISK IN AORTIC STENOSIS By Philippe Pibarot, DVM, PhD, FACC, FAHA Groupe de Recherche en Valvulopathies (GRV), Hôpital Laval Research Centre
More informationArteriosclerosis & Atherosclerosis
Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,
More informationTemperature-Sensitive Mutants Isolated from Hamster and
JOURNAL OF VIROLOGY, Nov. 1975, p. 1332-1336 Copyright i 1975 American Society for Microbiology Vol. 16, No. 5 Printed in U.S.A. Temperature-Sensitive Mutants Isolated from Hamster and Canine Cell Lines
More informationStatins in lung disease
Statins in lung disease Associate Professor Robert Young BMedSc, MBChB, DPhil (Oxon), FRACP, FRCP University of Auckland, New Zealand Smoking and its complications Respiratory COPD Cardiovascular CAD Smoking
More informationI. Lines of Defense Pathogen: Table 1: Types of Immune Mechanisms. Table 2: Innate Immunity: First Lines of Defense
I. Lines of Defense Pathogen: Table 1: Types of Immune Mechanisms Table 2: Innate Immunity: First Lines of Defense Innate Immunity involves nonspecific physical & chemical barriers that are adapted for
More informationTransmission of Chlamydia pneumoniae infection from blood monocytes to vascular cells in a novel transendothelial migration model
FEMS Microbiology Letters 242 (2005) 203 208 www.fems-microbiology.org Transmission of Chlamydia pneumoniae infection from blood monocytes to vascular cells in a novel transendothelial migration model
More informationIn vitro human regulatory T cell expansion
- 1 - Human CD4 + CD25 + CD127 dim/- regulatory T cell Workflow isolation, in vitro expansion and analysis In vitro human regulatory T cell expansion Introduction Regulatory T (Treg) cells are a subpopulation
More informationThe Prevalence of Chlamydia pneumoniae
152 JACC Vol. 33, No. 1 The Prevalence of Chlamydia pneumoniae in Atherosclerotic and Nonatherosclerotic Blood Vessels of Patients Attending for Redo and First Time Coronary Artery Bypass Graft Surgery
More informationPhosphate buffered saline (PBS) for washing the cells TE buffer (nuclease-free) ph 7.5 for use with the PrimePCR Reverse Transcription Control Assay
Catalog # Description 172-5080 SingleShot Cell Lysis Kit, 100 x 50 µl reactions 172-5081 SingleShot Cell Lysis Kit, 500 x 50 µl reactions For research purposes only. Introduction The SingleShot Cell Lysis
More informationPCR Is Not Always the Answer
PCR Is Not Always the Answer Nicholas M. Moore, PhD(c), MS, MLS(ASCP) CM Assistant Director, Division of Clinical Microbiology Assistant Professor Rush University Medical Center Disclosures Contracted
More informationDyslipidemia Endothelial dysfunction Free radicals Immunologic
ATHEROSCLEROSIS Hossein Mehrani Professor of Clinical Biochemistry Definition Atherosclerosis: Is a chronic inflammatory process characterized by plaque formation within the vessel wall of arteries and
More informationMaterials and Methods , The two-hybrid principle.
The enzymatic activity of an unknown protein which cleaves the phosphodiester bond between the tyrosine residue of a viral protein and the 5 terminus of the picornavirus RNA Introduction Every day there
More informationCytotoxic-T-Lymphocyte-Mediated Cytolysis of L Cells Persistently Infected with Chlamydia spp.
INFECTION AND IMMUNITY, June 1996, p. 1944 1949 Vol. 64, No. 6 0019-9567/96/$04.00 0 Copyright 1996, American Society for Microbiology Cytotoxic-T-Lymphocyte-Mediated Cytolysis of L Cells Persistently
More informationMicrobial Mechanisms of Pathogenicity & Innate Immunity: Nonspecific Defenses of the Host
Microbial Mechanisms of Pathogenicity & Innate Immunity: Nonspecific Defenses of the Host Microbial Mechanisms of Pathogenicity Pathogenicity: Virulence: The extent of pathogenicity. - function of: - infectivity
More informationCampbell's Biology: Concepts and Connections, 7e (Reece et al.) Chapter 24 The Immune System Multiple-Choice Questions
Campbell's Biology: Concepts and Connections, 7e (Reece et al.) Chapter 24 The Immune System 24.1 Multiple-Choice Questions 1) The body's innate defenses against infection include A) several nonspecific
More informationPBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human
Anti-CD19-CAR transduced T-cell preparation PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human AB serum (Gemini) and 300 international units/ml IL-2 (Novartis). T cell proliferation
More informationCommentary Persistent Chlamydiae and chronic arthritis Cheryl Villareal*, Judith A Whittum-Hudson* and Alan P Hudson*
Commentary Persistent Chlamydiae and chronic arthritis Cheryl Villareal*, Judith A Whittum-Hudson* and Alan P Hudson* *Department of Immunology and Microbiology, Wayne State University School of Medicine,
More informationNeutrophils contribute to fracture healing by synthesizing fibronectin+ extracellular matrix rapidly after injury
Neutrophils contribute to fracture healing by synthesizing fibronectin+ extracellular matrix rapidly after injury Bastian OW, Koenderman L, Alblas J, Leenen LPH, Blokhuis TJ. Neutrophils contribute to
More informationPERSISTENT INFECTIONS WITH HUMAN PARAINFLUENZAVIRUS TYPE 3 IN TWO CELL LINES
71 PERSISTENT INFECTIONS WITH HUMAN PARAINFLUENZAVIRUS TYPE 3 IN TWO CELL LINES Harold G. Jensen, Alan J. Parkinson, and L. Vernon Scott* Department of Microbiology & Immunology, University of Oklahoma
More informationThe aorta is an integral part of the cardiovascular system and should not be considered as just a conduit for blood supply from the heart to the
The aorta is an integral part of the cardiovascular system and should not be considered as just a conduit for blood supply from the heart to the limbs and major organs. A range of important pathologies
More informationLDL Uptake Cell-Based Assay Kit
LDL Uptake Cell-Based Assay Kit Item No. 10011125 www.caymanchem.com Customer Service 800.364.9897 Technical Support 888.526.5351 1180 E. Ellsworth Rd Ann Arbor, MI USA TABLE OF CONTENTS GENERAL INFORMATION
More informationReceived 22 February 1999/Returned for modification 17 March 1999/Accepted 26 March 1999
INFECTION AND IMMUNITY, June 1999, p. 2909 2915 Vol. 67, No. 6 0019-9567/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Chlamydia pneumoniae Infection of Human Endothelial
More informationMYCOBACTERIA. Pulmonary T.B. (infect bird)
MYCOBACTERIA SPP. Reservoir Clinical Manifestation Mycobacterium tuberculosis Human Pulmonary and dissem. T.B. M. lepra Human Leprosy M. bovis Human & cattle T.B. like infection M. avium Soil, water, birds,
More informationFORMATION OF A NOVEL PHAGOSOME BY THE LEGIONNAIRES' DISEASE BACTERIUM (LEGIONELLA
Published Online: 1 October, 1983 Supp Info: http://doi.org/10.1084/jem.158.4.1319 Downloaded from jem.rupress.org on August 31, 2018 FORMATION OF A NOVEL PHAGOSOME BY THE LEGIONNAIRES' DISEASE BACTERIUM
More informationLaboratory diagnosis of congenital infections
Laboratory diagnosis of congenital infections Laboratory diagnosis of HSV Direct staining Tzanck test Immunostaining HSV isolation Serology PCR Tzanck test Cell scrape from base of the lesion smear on
More informationChapter 6- An Introduction to Viruses*
Chapter 6- An Introduction to Viruses* *Lecture notes are to be used as a study guide only and do not represent the comprehensive information you will need to know for the exams. 6.1 Overview of Viruses
More informationImmune System. Name: Class: Date: Multiple Choice Identify the choice that best completes the statement or answers the question.
Class: Date: Immune System Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Which of the bacteria is the cause of pneumonia? a. staphylococci c. Treponema
More informationJournal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationRapid antigen-specific T cell enrichment (Rapid ARTE)
Direct ex vivo characterization of human antigen-specific CD154+CD4+ T cell Rapid antigen-specific T cell enrichment (Rapid ARTE) Introduction Workflow Antigen (ag)-specific T cells play a central role
More informationAcute coronary syndrome. Dr LM Murray Chemical Pathology Block SA
Acute coronary syndrome Dr LM Murray Chemical Pathology Block SA13-2014 Acute myocardial infarction (MI) MI is still the leading cause of death in many countries It is characterized by severe chest pain,
More informationFrances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS
The Laboratory s Role in Caring for Patients Diagnosed with TB Frances Morgan, PhD October 21, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE
More informationMedical management of abdominal aortic aneurysms
Medical management of abdominal aortic aneurysms Definition of AAA - Generally a 50% increase in native vessel diameter - Diameter 3 cm - Relative measures compared with nondiseased aortic segments less
More informationSestrin2 and BNIP3 (Bcl-2/adenovirus E1B 19kDa-interacting. protein3) regulate autophagy and mitophagy in renal tubular cells in. acute kidney injury
Sestrin2 and BNIP3 (Bcl-2/adenovirus E1B 19kDa-interacting protein3) regulate autophagy and mitophagy in renal tubular cells in acute kidney injury by Masayuki Ishihara 1, Madoka Urushido 2, Kazu Hamada
More informationThe atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae
The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae He Hu, 1 Grant N. Pierce, 2 and Guangming Zhong 1,3 1 Department of Medical Microbiology, 2
More information